{"nctId":"NCT01328951","briefTitle":"A Study of First-line Maintenance Erlotinib Versus Erlotinib at Disease Progression in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Platinum-Based Chemotherapy","startDateStruct":{"date":"2011-09"},"conditions":["Non-Squamous Non-Small Cell Lung Cancer"],"count":643,"armGroups":[{"label":"Early Erlotinib","type":"EXPERIMENTAL","interventionNames":["Drug: Erlotinib","Drug: Second-Line Chemotherapy"]},{"label":"Late Erlotinib","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Drug: Erlotinib"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"Erlotinib","otherNames":["Tarceva"]},{"name":"Second-Line Chemotherapy","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adults greater than or equal to (≥) 18 years of age, or legal age of consent if greater than 18\n* Advanced or recurrent (Stage IIIB) or metastatic (Stage IV) NSCLC\n* Completion of 4 cycles of platinum-based chemotherapy without progression (end of last chemotherapy cycle less than or equal to \\[≤\\] 28 days prior to randomization)\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n\nExclusion Criteria:\n\n* Prior exposure to agents directed at human epidermal growth factor receptor (HER) axis (e.g. erlotinib, gefitinib, cetuximab)\n* Participants whose tumors harbor an EGFR-activating mutation\n* Prior chemotherapy or therapy with systemic anti-neoplastic therapy for advanced disease before Screening\n* Use of pemetrexed in maintenance setting (pemetrexed allowed during the chemotherapy run-in)\n* Participants who have undergone complete tumor resection after responding to the platinum-based chemotherapy during the Screening phase\n* Any other malignancies within 5 years, except for curatively resected carcinoma in situ of the cervix, basal or squamous cell skin cancer, ductal carcinoma in situ, or organ-confined prostate cancer\n* Central nervous system (CNS) metastases or spinal cord compression that has not been definitely treated with surgery and/or radiation, or treated CNS metastases or spinal cord compression without stable disease for ≥2 months\n* Human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection\n* Any inflammatory changes of the surface of the eye","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Who Died During the Overall Study","description":"Participants were followed for survival until death or premature withdrawal. The percentage of participants who died during the Overall Study (BP, OLP, or SFU) was calculated.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.2","spread":null},{"groupId":"OG001","value":"75.2","spread":null}]}]}]},{"type":"PRIMARY","title":"Overall Survival (OS) as Median Time to Event During the Overall Study","description":"Participants were followed for survival until death or premature withdrawal. OS was defined as the interval between date of randomization and date of death from any cause. Median time to event during the Overall Study (BP, OLP, or SFU) was estimated using the Kaplan-Meier method and expressed in months.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.46","spread":null},{"groupId":"OG001","value":"9.72","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Event-Free (Alive) at 1 Year During the Overall Study","description":"Participants were followed for survival until death or premature withdrawal. The percentage of participants event-free (i.e., still alive) at 1 year during the Overall Study was calculated.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.75","spread":null},{"groupId":"OG001","value":"42.15","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Died or Experienced Disease Progression During Blinded Treatment","description":"Tumor response was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Disease progression was defined as a greater than or equal to (≥) 20 percent (%) and ≥5-millimeter (mm) increase in the sum of target lesion diameters in reference to the smallest sum on study and/or substantial worsening in non-target disease. The percentage of participants who died or experienced disease progression during the BP was calculated.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.0","spread":null},{"groupId":"OG001","value":"94.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-Free Survival (PFS) as Median Time to Event During Blinded Treatment","description":"Tumor response was evaluated using RECIST version 1.1. Disease progression was defined as a ≥20% and ≥5-mm increase in the sum of target lesion diameters in reference to the smallest sum on study and/or substantial worsening in non-target disease. PFS was defined as the interval between date of randomization and date of first documented death or disease progression. Median time to event during the BP was estimated using the Kaplan-Meier method and expressed in weeks.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.00","spread":null},{"groupId":"OG001","value":"13.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Event-Free (Alive and No Disease Progression) at 6 Months During Blinded Treatment","description":"Tumor response was evaluated using RECIST version 1.1. Disease progression was defined as a ≥20% and ≥5-mm increase in the sum of target lesion diameters in reference to the smallest sum on study and/or substantial worsening in non-target disease. The percentage of participants event-free (i.e., still alive and without disease progression) at 6 months during the BP was calculated.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.22","spread":null},{"groupId":"OG001","value":"27.11","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Complete Response (CR) or Partial Response (PR) According to RECIST During Blinded Treatment","description":"Tumor response was evaluated using RECIST version 1.1. CR was defined as disappearance of all target and non-target lesions and short-axis reduction to less than (\\<) 10 mm of any pathological lymph nodes. PR was defined as a ≥30% decrease in the sum of target lesion diameters in reference to the Baseline sum. The percentage of participants with a best overall response of either CR or PR (i.e., the objective response rate \\[ORR\\]) during the BP was calculated, and corresponding 95% CI was constructed using the Pearson-Clopper method.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":null},{"groupId":"OG001","value":"6.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants by Best Overall Response According to RECIST During Blinded Treatment","description":"Tumor response was evaluated using RECIST version 1.1. CR was defined as disappearance of all target and non-target lesions and short-axis reduction to \\<10 mm of any pathological lymph nodes. PR was defined as a ≥30% decrease in the sum of target lesion diameters in reference to the Baseline sum. Stable disease (SD) was defined as neither sufficient shrinkage in target lesions to qualify for PR nor sufficient growth to qualify for disease progression. Disease progression (progressive disease/PD) was defined as a ≥20% and ≥5-mm increase in the sum of target lesion diameters in reference to the smallest sum on study and/or substantial worsening in non-target disease. The percentage of participants with each level of best tumor response during the BP was calculated, and corresponding 95% CI was constructed using the Pearson-Clopper method.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":null},{"groupId":"OG001","value":"0.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":null},{"groupId":"OG001","value":"5.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.5","spread":null},{"groupId":"OG001","value":"54.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.6","spread":null},{"groupId":"OG001","value":"32.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":null},{"groupId":"OG001","value":"6.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With CR, PR, or SD According to RECIST During Blinded Treatment","description":"Tumor response was evaluated using RECIST version 1.1. CR was defined as disappearance of all target and non-target lesions and short-axis reduction to \\<10 mm of any pathological lymph nodes. PR was defined as a ≥30% decrease in the sum of target lesion diameters in reference to the Baseline sum. SD was defined as neither sufficient shrinkage in target lesions to qualify for PR nor sufficient growth to qualify for disease progression. The percentage of participants with a best overall response of CR, PR, or SD (i.e., the disease control rate \\[DCR\\]) during the BP was calculated, and corresponding 95% CI was constructed using the Pearson-Clopper method.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.2","spread":null},{"groupId":"OG001","value":"61.2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":27,"n":319},"commonTop":["Rash","Diarrhoea","Cough","Dyspnoea","Fatigue"]}}}